Literature DB >> 28856386

[Focal therapy of prostate cancer].

R Ganzer1, T Franiel2, J Köllermann3, T Kuru4, D Baumunk5, A Blana6, B Hadaschik7, J von Hardenberg8, T Henkel9, K-U Köhrmann10, U-B Liehr11, S Machtens12, A Roosen13, G Salomon14, H-P Schlemmer15, L Sentker16, J Wendler11, U Witzsch17, M Schostak11.   

Abstract

The target of focal therapy (FT) in prostate cancer (PC) is partial treatment of the prostate aiming at preserving surrounding anatomical structures. The intention is to minimize typical side effects of radical treatment options combined with local tumor control. Numerous established and new technologies are used. Results of published studies showed a good safety profile, few side effects and good preservation of functional results. Oncologic long-term data are lacking so far. Photodynamic therapy (PDT) is the only technology that has been studied in a published prospective randomized trial. The FT is challenged by the multifocality of PC; therefore, the quality of prostate biopsy, histopathological assessment as well as imaging are of paramount importance. Multiparametric magnetic resonance imaging (MRI) has gained increasing importance. The FT is experimental and should only be offered within clinical trials.

Entities:  

Keywords:  Cryotherapy; High intensity focused ultrasound (HIFU); Irreversible electroporation; Multiparametric magnetic resonance imaging; Prostatic neoplasms

Mesh:

Substances:

Year:  2017        PMID: 28856386     DOI: 10.1007/s00120-017-0488-z

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  39 in total

1.  Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years.

Authors:  Duke Bahn; Andre Luis de Castro Abreu; Inderbir S Gill; Andrew J Hung; Paul Silverman; Mitchell E Gross; Gary Lieskovsky; Osamu Ukimura
Journal:  Eur Urol       Date:  2012-03-21       Impact factor: 20.096

2.  Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial.

Authors:  Abdel-Rahmène Azzouzi; Sébastien Vincendeau; Eric Barret; Antony Cicco; François Kleinclauss; Henk G van der Poel; Christian G Stief; Jens Rassweiler; Georg Salomon; Eduardo Solsona; Antonio Alcaraz; Teuvo T Tammela; Derek J Rosario; Francisco Gomez-Veiga; Göran Ahlgren; Fawzi Benzaghou; Bertrand Gaillac; Billy Amzal; Frans M J Debruyne; Gaëlle Fromont; Christian Gratzke; Mark Emberton
Journal:  Lancet Oncol       Date:  2016-12-20       Impact factor: 41.316

3.  Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database (COLD) Registry.

Authors:  John F Ward; J Stephen Jones
Journal:  BJU Int       Date:  2011-10-28       Impact factor: 5.588

4.  Re-evaluating the concept of "dominant/index tumor nodule" in multifocal prostate cancer.

Authors:  Cheng Cheng Huang; Fang-Ming Deng; Max X Kong; Qinhu Ren; Jonathan Melamed; Ming Zhou
Journal:  Virchows Arch       Date:  2014-03-12       Impact factor: 4.064

5.  The Relationship between Intolerance of Uncertainty and Anxiety in Men on Active Surveillance for Prostate Cancer.

Authors:  Hung-Jui Tan; Leonard S Marks; Michael A Hoyt; Lorna Kwan; Christopher P Filson; Malu Macairan; Patricia Lieu; Mark S Litwin; Annette L Stanton
Journal:  J Urol       Date:  2016-02-09       Impact factor: 7.450

6.  Partial Gland Treatment of Prostate Cancer Using High-Intensity Focused Ultrasound in the Primary and Salvage Settings: A Systematic Review.

Authors:  Ron Golan; Adrien N Bernstein; Timothy D McClure; Art Sedrakyan; Neal A Patel; Dipen J Parekh; Leonard S Marks; Jim C Hu
Journal:  J Urol       Date:  2017-04-19       Impact factor: 7.450

7.  Assessment of PI-RADS v2 for the Detection of Prostate Cancer.

Authors:  Moritz Kasel-Seibert; Thomas Lehmann; René Aschenbach; Felix V Guettler; Mohamed Abubrig; Marc-Oliver Grimm; Ulf Teichgraeber; Tobias Franiel
Journal:  Eur J Radiol       Date:  2016-01-19       Impact factor: 3.528

8.  Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management.

Authors:  Gary Onik; Matthew Miessau; David G Bostwick
Journal:  J Clin Oncol       Date:  2009-08-03       Impact factor: 44.544

9.  Image guided photothermal focal therapy for localized prostate cancer: phase I trial.

Authors:  U Lindner; R A Weersink; M A Haider; M R Gertner; S R H Davidson; M Atri; B C Wilson; A Fenster; J Trachtenberg
Journal:  J Urol       Date:  2009-08-14       Impact factor: 7.450

10.  Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.

Authors:  Hashim U Ahmed; Ahmed El-Shater Bosaily; Louise C Brown; Rhian Gabe; Richard Kaplan; Mahesh K Parmar; Yolanda Collaco-Moraes; Katie Ward; Richard G Hindley; Alex Freeman; Alex P Kirkham; Robert Oldroyd; Chris Parker; Mark Emberton
Journal:  Lancet       Date:  2017-01-20       Impact factor: 79.321

View more
  1 in total

Review 1.  Interventional therapy in malignant conditions of the prostate.

Authors:  Attila Kovács; Michael Pinkawa
Journal:  Radiologe       Date:  2019-12       Impact factor: 0.635

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.